29 Quotes by Paul Donovan

We continue to expect to be in a position to sign a definitive agreement in the first two weeks of January.

We continue to believe our $72 proposal is better for Guidant, its shareholders and its employees than Johnson & Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time. We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant.

We continue to believe our $72 (per share) proposal is better for Guidant, its shareholders and its employees than Johnson & Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time. We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant.

We continue to believe our $72 (a share) proposal is better for Guidant, its shareholders and its employees than Johnson & Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time.

We believe this issue has no bearing on our proposed acquisition of Guidant. Unfortunately, threats of legal action are commonplace in our industry.

We will recommend changes designed to ensure that the final regulation preserves the fullest possible beneficiary access to innovative technologies and therapies.

We have brought a lot of companies into the Boston Scientific family and we have never been more confident or enthusiastic about the prospects for a merger.

We are seeing a belief that the Japanese economy is recovering. The Japanese are going to keep their money at home and overseas investors are going to put more to work in Japan.

We should have things re-stocked in a few weeks.